NasdaqGS:VRTXBiotechs
Is Vertex Pharmaceuticals (VRTX) Cheap Following Its Raised 2026 Revenue Guidance?
Vertex Pharmaceuticals (VRTX) lifted its full year 2026 revenue guidance after citing continued demand in cystic fibrosis treatments and broader uptake in sickle cell disease, beta thalassemia, and acute pain therapies.
See our latest analysis for Vertex Pharmaceuticals.
The guidance upgrade comes after a strong run in Vertex Pharmaceuticals stock, with a 30 day share price return of 15.97% and a 90 day share price return of 26.13%. The 1 year total shareholder return of 38.70% and 5 year...